CMS Rule Undermines Real Cost Savings For Consumers & Could Cripple Fledgling U.S. Biosimilar Market

The Obama administration is proposing a Medicare payment rule that would have the effect of clamping price controls on biosimilar drugs, extending destructive pricing policies to a potentially vibrant 21st century life sciences industry. The Centers for Medicare and Medicaid Services (CMS) has proposed a rule that would guide how Medicare pays for a...

A Bad-Actor, Not A Pharmaceutical Innovator, Causes Outrage Over Drug Prices

A profiteer masquerading as a pharmaceutical company executive has set the Internet afire with his 5,000% price increase for a rare but important drug used by AIDS and some cancer patients. Martin Shkreli, a 32-year-old former hedge fund manager, cornered the market on Daraprim, a drug used to treat a life-threatening parasitic infection. His...

First Biosimilar Medicine Launches; Price Disappoints Those Hoping For Deeper Discount

Pharmaceutical prices are dominating public concerns about health care, according to a recent poll by the Kaiser Family Foundation that shows three-quarters of Americans support limiting how much drug companies can charge for high-cost drugs.  So it’s especially disappointing to see that the first imitators of a new generation of biologic cancer drugs approved...